Ancient Chinese Herbal Formula Shows Early Promise Against PCOS Inflammation

Polycystic ovary syndrome, or PCOS, is one of the most common endocrine disorders in the world, affecting an estimated twenty percent of women of reproductive age. Its hallmark features—chronic anovulation, elevated androgens, and polycystic ovarian morphology—have long been framed as problems of hormones and metabolism. But a growing body of evidence points to another, quieter player: chronic low-grade inflammation, a persistent, smoldering immune state that elevates inflammatory cytokines in the blood and, crucially, in the ovary itself. A new study published in Immunity, Inflammation and Disease now reports that a traditional Chinese herbal formula called Bushen Huatan Formula, or BHF, can dampen this inflammatory fire in an obese rat model of PCOS, and that its effects appear strongest when treatment begins early in the disease process.

The research team, led by investigators affiliated with Heilongjiang University of Chinese Medicine, took an unusually systematic approach. Because PCOS is a heterogeneous, multifactorial disorder and because traditional herbal formulas contain dozens of chemically active compounds acting on many targets simultaneously, the researchers first turned to network pharmacology. This computational strategy treats a disease and a drug as vast interaction networks and searches for the points where they overlap. The team screened the chemical constituents of BHF’s five herbs—Huang Qi (Astragalus membranaceus), Yin Yang Huo (Herba epimedii), Cang Zhu (Rhizoma atractylodis), Fu Ling (Poria cocos), and Dan Shen (Salvia miltiorrhiza)—using the TCMSP database, applying strict filters for oral bioavailability and drug-likeness. The screen yielded 101 active chemical components and 218 predicted protein targets.

Cross-referencing those drug targets against 5,836 PCOS-related targets harvested from the GeneCards and OMIM databases produced a set of 169 intersecting targets. From there, the researchers built a herb–component–target network in Cytoscape and ranked the ingredients by their degree values, a topological measure of how many other network nodes a given compound connects to. Luteolin, a flavonoid with 116 connections, topped the list, followed by wogonin, tanshinone IIA, formononetin, isorhamnetin, and several other molecules with documented anti-inflammatory and metabolic activity. Protein–protein interaction analysis then distilled the target network down to ten hub proteins: AKT1, TNF, IL6, TP53, ESR1, CASP3, EGFR, IL1B, PTGS2, and MMP9—names that will be immediately familiar to anyone who studies inflammation, apoptosis, insulin signaling, or ovarian steroidogenesis.

Enrichment analysis added a pathway-level view. The intersecting targets clustered in the AGE-RAGE signaling pathway in diabetic complications, the IL-17 and MAPK pathways, estrogen signaling, insulin resistance, and—most relevant to this study—the NF-κB signaling pathway. To probe whether the predicted compounds could actually engage their predicted targets, the team performed molecular docking with AutoDock Vina across one hundred compound–protein pairs. Sixty-six of these interactions showed strong binding affinity below −7.0 kcal/mol, indicating thermodynamically stable ligand–receptor complexes. Notably, tanshinone IIA, a diterpenoid from Dan Shen, bound PTGS2—the gene encoding cyclooxygenase-2—more tightly than any other pairing tested, flagging it as a potential lead compound.

Computational predictions, however, are only hypotheses until they meet wet-lab reality. To validate the network findings, the researchers used letrozole, an aromatase inhibitor, to induce PCOS in female Wistar rats via continuous-release pellets. Critically, they examined the animals at two time points—six weeks and twelve weeks after pellet implantation—to capture the dynamic evolution of the disease rather than a single endpoint. The letrozole model reproduced the metabolic and reproductive abnormalities seen in clinical PCOS: treated rats gained significantly more weight, accumulated more inguinal fat, and showed elevated fasting blood glucose compared with controls, with all measures worsening between the six- and twelve-week marks. Histology told a parallel story. While the ovaries of early-stage rats looked largely normal, the twelve-week group developed frank cystic follicular dilation, follicular atresia, and thinning of the granulosa cell layers—textbook signs of established PCOS.

The inflammatory signature emerged early and deepened over time. Immunohistochemistry revealed increased TLR4 and NF-κB protein staining in both ovarian and inguinal fat tissues of the twelve-week model, and a qPCR array of ninety-two NF-κB signaling targets detected significant shifts in genes including ACTB, C3, CXCL3, NQO1, and SELP. When the team isolated granulosa cells—the somatic cells that nurture developing oocytes and are essential for ovulation—they found dramatically elevated secretion of TNF-α, IL-1β, IL-6, IL-8, lipopolysaccharide-binding protein, LPS itself, CD14, and high-sensitivity C-reactive protein. Several of these markers, including IL-1β, IL-6, IL-8, and LPS, rose further between the six- and twelve-week stages, confirming that the inflammatory microenvironment of the PCOS ovary is not static but progressively escalating. The LPS–LBP–CD14 module is particularly significant mechanistically, because this triad is the canonical activator of TLR4, the innate immune receptor that switches on NF-κB and triggers the transcriptional program of chronic inflammation.

Enter the herbal formula. The researchers prepared BHF-containing serum by dosing healthy rats with the decoction and collecting their blood, then co-cultured this serum with granulosa cells isolated from the PCOS animals. The results were striking. In cells from six-week PCOS rats, BHF serum significantly reduced all eight inflammatory markers compared with cells treated with control serum, essentially reversing the heightened inflammatory state. In cells from twelve-week rats, BHF again lowered TNF-α, IL-1β, IL-6, IL-8, LBP, LPS, CD14, and hsCRP—but the reduction was only partial, and treated diseased cells still secreted significantly more inflammatory factors than treated healthy cells. In other words, the formula could suppress inflammation at both stages, but early-stage disease responded far more completely.

This stage-dependence is arguably the study’s most important translational message. It suggests that the chronic low-grade inflammatory state in PCOS precedes the full establishment of the syndrome and may actively contribute to its progression, and that therapeutic windows matter: once the inflammatory loop becomes entrenched, even a multi-target intervention cannot fully unwind it. The finding echoes a core principle of traditional Chinese medicine—“preventing disease before it progresses”—and aligns with the modern concept of early intervention in chronic inflammatory and metabolic disease. Because NF-κB sits at the hub of the cytokine network, feeding back on its own activation through TNF-α and sustaining IL-6 signaling via JAK/STAT3, breaking the loop early may prevent the self-perpetuating inflammation that disrupts granulosa cell steroidogenesis and ultimately ovulation itself.

The authors are appropriately candid about the limitations. The work was conducted entirely in rats and isolated cells; the letrozole model recapitulates only part of the heterogeneous human phenotype; TLR4/NF-κB activation was assessed by immunohistochemistry and gene expression rather than phospho-specific or loss-of-function experiments, so causation remains to be proven; the formula batch was not chemically fingerprinted; and hormonal endpoints such as testosterone and estrous cyclicity were not measured. Human validation—in granulosa cells, follicular fluid, and clinical cohorts—is the essential next step. Still, the convergence of computational prediction, molecular docking, and experimental data provides a rare level of mechanistic coherence for a multi-herb formula. If confirmed, BHF’s ability to modulate the TLR4/NF-κB axis could open a genuinely new direction for managing the inflammatory component of PCOS, one rooted in centuries of empirical practice but tested with thoroughly modern tools.

Subject of Research: Effects of the Bushen Huatan Formula on chronic low-grade inflammation in obese PCOS via the TLR4/NF-κB signaling pathway

Article Title: Bushen Huatan Formula Ameliorates Early Chronic Low‐Grade Inflammation in Obese PCOS Via the TLR4/NF‐κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study

Article References: Zhang, J., Gu, F., Li, Y., Feng, X., Kuang, H., Xu, F., & Sun, M. (2026). Bushen Huatan Formula Ameliorates Early Chronic Low‐Grade Inflammation in Obese PCOS Via the TLR4/NF‐κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study. Immunity, Inflammation and Disease, 14(9), Article e70518. https://doi.org/10.1002/iid3.70518

Image Credits: AI Generated

DOI: 10.1002/iid3.70518

Keywords: PCOS, chronic low-grade inflammation, Bushen Huatan Formula, TLR4/NF-κB pathway, network pharmacology, molecular docking, granulosa cells, traditional Chinese medicine, letrozole-induced rat model, inflammatory cytokines, ovarian inflammation, insulin resistance